You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDipyridamole
Accession NumberDB00975  (APRD00360)
TypeSmall Molecule
GroupsApproved
Description

A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Structure
Thumb
Synonyms
Cardoxin
Cleridium 150
Curantyl
Dipiridamol
Dipyridamine
Dipyridamolum
Dipyudamine
Dypyridamol
Persantin
External Identifiers
  • USAF GE-12
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dipyridamoletablet25 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamoletablet75 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamoletablet25 mg/1oralCarilion Materials Management2012-02-15Not applicableUs
Dipyridamoletablet50 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamole 25 Tab 25mgtablet25 mgoralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 50 Tab 50mgtablet50 mgoralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 75 Tabtablet75 mgoralPro Doc Limitee1984-12-312002-08-02Canada
Dipyridamole for Injectionsolution5 mgintravenousNovopharm Limited2002-04-30Not applicableCanada
Dipyridamole Injection, USPliquid5 mgintravenousFresenius Kabi Canada Ltd2002-04-23Not applicableCanada
Dipyridamole-25tablet25 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-50tablet50 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-75tablet75 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Novo-dipiradol Sct 100mgtablet100 mgoralNovopharm Limited1991-12-312005-08-10Canada
Novo-dipiradol Tab 25mgtablet25 mgoralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 50mgtablet50 mgoralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 75mgtablet75 mgoralNovopharm Limited1989-12-312005-08-10Canada
Persantinesolution5 mgintravenousBoehringer Ingelheim (Canada) Ltd Ltee1986-12-31Not applicableCanada
Persantinetablet, coated75 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantinetablet, coated50 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantinetablet, coated25 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantine Tab 100mgtablet100 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1985-12-312002-07-25Canada
Persantine Tab 25mgtablet25 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1962-12-312005-02-14Canada
Persantine Tab 50mgtablet50 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1968-12-312011-03-03Canada
Persantine Tab 75mgtablet75 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1981-12-312010-06-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dipyridamole-FC Tab 25mgtablet25 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 50mgtablet50 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 75mgtablet75 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 25mgtablet25 mgoralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 50mgtablet50 mgoralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 75mgtablet75 mgoralApotex Inc1984-12-31Not applicableCanada
Dipyridamoletablet, film coated75 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet25 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralBarr Laboratories Inc.1980-10-01Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralCardinal Health2008-10-30Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoleinjection, solution5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralAv Pak2011-08-052016-01-15Us
Dipyridamoleinjection5 mg/mLintravenousWest Ward Pharmaceutical Corp.1996-10-18Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralAv Pak2011-08-052016-01-15Us
Dipyridamoletablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-23Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-11-17Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralRising Pharmaceuticals, Inc.2007-08-05Not applicableUs
Dipyridamoletablet75 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAv Pak2007-08-052016-01-15Us
Dipyridamoletablet, film coated75 mg/1oralBarr Laboratories Inc.1982-01-01Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralCardinal Health2011-08-05Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralBarr Laboratories Inc.1982-01-01Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralCardinal Health2008-10-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dipyridamolesolution5 mg/mLintravenousAnazao Health Corporation2012-05-23Not applicableUs
International Brands
NameCompany
Agileaselsei
CardoxinRafa
Cleridium 150Millot
CurantylArzneimittelwerk
PersantinNot Available
Brand mixtures
NameLabellerIngredients
AggrenoxBoehringer Ingelheim Pharmaceuticals, Inc.
Asasantine CapBoehringer Ingelheim (Canada) Ltd Ltee
Aspirin and DipyridamoleRoxane Laboratories, Inc.
SaltsNot Available
Categories
UNII64ALC7F90C
CAS number58-32-2
WeightAverage: 504.6256
Monoisotopic: 504.317251808
Chemical FormulaC24H40N8O4
InChI KeyInChIKey=IZEKFCXSFNUWAM-UHFFFAOYSA-N
InChI
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
IUPAC Name
2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol
SMILES
OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentDialkylarylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Aminopyrimidine
  • Imidolactam
  • Pyrimidine
  • Piperidine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
PharmacodynamicsDipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.
Mechanism of actionDipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
Related Articles
Absorption70%
Volume of distribution
  • 1 to 2.5 L/kg
Protein binding99%
Metabolism

hepatic

Route of eliminationDipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.
Half life40 minutes
Clearance
  • 2.3-3.5 mL/min/kg
ToxicityHypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dipyridamole (Antiplatelet) Action PathwayDrug actionSMP00264
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier-0.6246
Caco-2 permeable-0.7261
P-glycoprotein substrateSubstrate0.7696
P-glycoprotein inhibitor INon-inhibitor0.5321
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.615
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.6825
CYP450 3A4 substrateNon-substrate0.6849
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8045
CYP450 2D6 inhibitorInhibitor0.7201
CYP450 2C19 inhibitorNon-inhibitor0.957
CYP450 3A4 inhibitorInhibitor0.6789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7806
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.8884
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.1167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5271
hERG inhibition (predictor II)Non-inhibitor0.633
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Glenmark generics inc usa
  • Impax laboratories inc
  • Lannett holdings inc
  • Murty pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Boehringer Ingelheim Pharmaceuticals, Inc
Packagers
Dosage forms
FormRouteStrength
Capsule (extended release); capsule (immediate release)oral
Tabletoral25 mg
Tabletoral50 mg
Tabletoral75 mg
Capsuleoral
Injectionintravenous5 mg/mL
Injection, solutionintravenous5 mg/mL
Solutionintravenous5 mg/mL
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral75 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Liquidintravenous5 mg
Tabletoral100 mg
Solutionintravenous5 mg
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, coatedoral75 mg/1
Prices
Unit descriptionCostUnit
Dipyridamole powder5.34USD g
Aggrenox capsule sa3.25USD capsule
Aggrenox 25-200 mg 12 Hour Capsule3.0USD capsule
Dipyridamole 5 mg/ml ampul1.5USD ml
Persantine 75 mg tablet1.46USD tablet
Dipyridamole 5 mg/ml vial1.32USD ml
Dipyridamole 75 mg tablet1.28USD tablet
Persantine 50 mg tablet1.09USD tablet
Dipyridamole 50 mg tablet0.96USD tablet
Persantine 25 mg tablet0.89USD tablet
Dipyridamole 25 mg tablet0.58USD tablet
Apo-Dipyridamole (Fc) 75 mg Tablet0.46USD tablet
Apo-Dipyridamole (Fc) 50 mg Tablet0.31USD tablet
Apo-Dipyridamole (Fc) 25 mg Tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6015577 No1997-01-182017-01-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point163 °CPhysProp
water solubilitySlightlyNot Available
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.922 mg/mLALOGPS
logP1.52ALOGPS
logP1.81ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.97ChemAxon
pKa (Strongest Basic)6.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area145.44 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity142.78 m3·mol-1ChemAxon
Polarizability56.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
References
Synthesis Reference

Minutza Leibovici, Itamar Kanari, Michael Fox, “Dipyridamole extended-release formulations and process for preparing same.” U.S. Patent US20070184110, issued August 09, 2007.

US20070184110
General References
  1. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. [PubMed:8981292 ]
External Links
ATC CodesB01AC07
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (48.7 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
AbciximabDipyridamole may increase the anticoagulant activities of Abciximab.
AcebutololDipyridamole may increase the bradycardic activities of Acebutolol.
AcenocoumarolDipyridamole may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Acetylsalicylic acid.
AdenosineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dipyridamole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.
AlteplaseDipyridamole may increase the anticoagulant activities of Alteplase.
AnistreplaseDipyridamole may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Apixaban.
AtenololDipyridamole may increase the bradycardic activities of Atenolol.
BetaxololDipyridamole may increase the bradycardic activities of Betaxolol.
BisoprololDipyridamole may increase the bradycardic activities of Bisoprolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dipyridamole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.
ButabarbitalButabarbital may increase the hypotensive activities of Dipyridamole.
ButethalButethal may increase the hypotensive activities of Dipyridamole.
CarteololDipyridamole may increase the bradycardic activities of Carteolol.
CarvedilolDipyridamole may increase the bradycardic activities of Carvedilol.
Citric AcidDipyridamole may increase the anticoagulant activities of Citric Acid.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dipyridamole.
CollagenaseThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dipyridamole.
DalteparinDipyridamole may increase the anticoagulant activities of Dalteparin.
DasatinibDasatinib may increase the anticoagulant activities of Dipyridamole.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic Acid.
DicoumarolDipyridamole may increase the anticoagulant activities of Dicoumarol.
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Dipyridamole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dipyridamole.
DuloxetineDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.
Edetic AcidDipyridamole may increase the anticoagulant activities of Edetic Acid.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dipyridamole.
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Dipyridamole.
EnoxaparinDipyridamole may increase the anticoagulant activities of Enoxaparin.
EsmololDipyridamole may increase the bradycardic activities of Esmolol.
Ethyl biscoumacetateDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.
Fondaparinux sodiumDipyridamole may increase the anticoagulant activities of Fondaparinux sodium.
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.
GlucosamineGlucosamine may increase the antiplatelet activities of Dipyridamole.
HeparinDipyridamole may increase the anticoagulant activities of Heparin.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Dipyridamole.
HexobarbitalHexobarbital may increase the hypotensive activities of Dipyridamole.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dipyridamole.
LabetalolDipyridamole may increase the bradycardic activities of Labetalol.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dipyridamole.
LevodopaDipyridamole may increase the orthostatic hypotensive activities of Levodopa.
LimaprostLimaprost may increase the antiplatelet activities of Dipyridamole.
MethohexitalMethohexital may increase the hypotensive activities of Dipyridamole.
MetoprololDipyridamole may increase the bradycardic activities of Metoprolol.
NadololDipyridamole may increase the bradycardic activities of Nadolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dipyridamole.
NebivololDipyridamole may increase the bradycardic activities of Nebivolol.
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Dipyridamole.
NicorandilNicorandil may increase the hypotensive activities of Dipyridamole.
ObinutuzumabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Dipyridamole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.
PenbutololDipyridamole may increase the bradycardic activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Dipyridamole.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Dipyridamole.
PhenindioneDipyridamole may increase the anticoagulant activities of Phenindione.
PhenprocoumonDipyridamole may increase the anticoagulant activities of Phenprocoumon.
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.
PindololDipyridamole may increase the bradycardic activities of Pindolol.
PrimidonePrimidone may increase the hypotensive activities of Dipyridamole.
PropranololDipyridamole may increase the bradycardic activities of Propranolol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dipyridamole.
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dipyridamole.
RegadenosonThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.
ReteplaseDipyridamole may increase the anticoagulant activities of Reteplase.
RidogrelDipyridamole may increase the anticoagulant activities of Ridogrel.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dipyridamole.
RiociguatDipyridamole may increase the hypotensive activities of Riociguat.
RisperidoneDipyridamole may increase the hypotensive activities of Risperidone.
RivaroxabanDipyridamole may increase the anticoagulant activities of Rivaroxaban.
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dipyridamole.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Dipyridamole.
SecobarbitalSecobarbital may increase the hypotensive activities of Dipyridamole.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.
SotalolDipyridamole may increase the bradycardic activities of Sotalol.
StreptokinaseDipyridamole may increase the anticoagulant activities of Streptokinase.
SulodexideDipyridamole may increase the anticoagulant activities of Sulodexide.
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole.
TenecteplaseDipyridamole may increase the anticoagulant activities of Tenecteplase.
TimololDipyridamole may increase the bradycardic activities of Timolol.
TipranavirTipranavir may increase the antiplatelet activities of Dipyridamole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dipyridamole.
TositumomabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.
TreprostinilDipyridamole may increase the anticoagulant activities of Treprostinil.
UrokinaseDipyridamole may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Dipyridamole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.
Vitamin EVitamin E may increase the antiplatelet activities of Dipyridamole.
WarfarinDipyridamole may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Coffee and tea can decrease the effect of dipyridamole.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999 Jun 25;274(26):18438-45. [PubMed:10373451 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):789-99. [PubMed:15672122 ]
  2. Santini F, Casali G, Franchi G, Auriemma S, Lusini M, Barozzi L, Favaro A, Messina A, Mazzucco A: Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. Int J Cardiol. 2005 Aug 18;103(2):156-63. [PubMed:16080974 ]
  3. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J: Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia. 2006 Aug;26(8):925-33. [PubMed:16886928 ]
  4. Jackson EK, Ren J, Zacharia LC, Mi Z: Characterization of renal ecto-phosphodiesterase. J Pharmacol Exp Ther. 2007 May;321(2):810-5. Epub 2007 Feb 16. [PubMed:17308037 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762 ]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
  3. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 29, 2016 01:51